ReviewInfection and drug resistance2015
Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.
Review in Infection and drug resistance, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 256 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
256 citing papers in PubMed, 3 syntheses or guidelines pooled it, 500 citations in OpenAlex.
- Intrawound vancomycin for prevention of surgical site infection: meta-analysis of randomized clinical trials.BJS open · 2026Pooled it
- Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European Region, 1 January 2010 to 4 February 2020.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Pooled it
- Clinical practice guidelines for the provision of renal service in Hong Kong: Infection Control in Renal Service.Nephrology (Carlton, Vic.) · 2019Guideline
- Trial
- Vancomycin-Resistant, ThermotolerantFoods (Basel, Switzerland) · 2026Article
- Factors associated with methicillin resistance in Staphylococcus aureus: a case-case-control analysis of AMR surveillance data.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Resistance to Human-Reserved Antimicrobials in Clinical and CommensalAntibiotics (Basel, Switzerland) · 2026Article
- Development of an Assay Involving Loop-Mediated Isothermal Amplification with a Lateral Flow Dipstick for Detection of theInternational journal of molecular sciences · 2026Article
- Antimicrobial Stewardship in Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- `Successful treatment of VRE-infected mice with vancomycin through restoration of susceptibility using vanA antisense RNA.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Detection of vanA-positive, glycopeptide-resistant but ampicillin-susceptible Enterococcus faecalis: two genetically distinct, unrelated clinical isolates from the United Kingdom.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faecium.Nature communications · 2026Article
- Comparative Analysis of Antimicrobial Resistance in Male Uropathogens Before and After the COVID-19 Pandemic: A Single-Center Study from Romania.Medicina (Kaunas, Lithuania) · 2026Article
- Dynamic screening strategies for the control of a prolonged vancomycin-resistant enterococci outbreak: A decade-long study in a Japanese tertiary hospital.Epidemiology and infection · 2026Article
- Antimicrobial resistance patterns in UTIs in male patients with associated kidney stone disease: a descriptive study.Journal of medicine and life · 2026Observational
- Recent advances in multimodal imaging of infections: research highlights using Nuclear-Optical imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Two decades of ESKAPE pathogens: Longitudinal analysis of antibiotic resistance trends between 2002 and 2024 in a Hungarian clinical centre.Epidemiology and infection · 2026Article
- Selectivity Modulation of Small Cationic Membrane-Active Cyclic Peptides with Broad-Spectrum Activity against Bacteria and Fungi.Journal of medicinal chemistry · 2026Article
- Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistantbioRxiv : the preprint server for biology · 2026Article
- Vancomycin resistance in gram-positive infections: evolutionary strategies of survival.Archives of microbiology · 2026Review
196 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its discovery in England and France in 1986, vancomycin-resistant Enterococcus has increasingly become a major nosocomial pathogen worldwide. Enterococci are prolific colonizers, with tremendous genome plasticity and a propensity for persistence in hospital environments, allowing for increased transmission and the dissemination of resistance elements. Infections typically present in immunosuppressed patients who have received multiple courses of antibiotics in the past. Virulence is variable, and typical clinical manifestations include bacteremia, endocarditis, intra-abdominal and pelvic infections, urinary tract infections, skin and skin structure infections, and, rarely, central nervous system infections. As enterococci are common colonizers, careful consideration is needed before initiating targeted therapy, and source control is first priority. Current treatment options including linezolid, daptomycin, quinupristin/dalfopristin, and tigecycline have shown favorable activity against various vancomycin-resistant Enterococcus infections, but there is a lack of randomized controlled trials assessing their efficacy. Clearer distinctions in preferred therapies can be made based on adverse effects, drug interactions, and pharmacokinetic profiles. Although combination therapies and newer agents such as tedizolid, telavancin, dalbavancin, and oritavancin hold promise for the future treatment of vancomycin-resistant Enterococcus infections, further studies are needed to assess their possible clinical impact, especially in the treatment of serious infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.